Ajanta Pharma has received final approval of Zolmitriptan tablets (2.5mg, 5mg) from the U.S. Food and Drug Administration (FDA). Zolmitriptan is used in the acute treatment of migraine and is an equivalent generic version of Zomig1.
Zolmitriptan Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the U.S. market. To date, the United States Food & Drug Administration (U.S.FDA) has granted Ajanta Pharma 9 ANDA final approvals and 2 tentative approvals. Additional 15 ANDAs are under review with the FDA.
Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: